000153422 001__ 153422
000153422 005__ 20230915094021.0
000153422 0247_ $$2doi$$a10.5414/NP301278
000153422 037__ $$aDZNE-2020-01419
000153422 041__ $$aEnglish
000153422 082__ $$a610
000153422 1001_ $$aRiemenschneider, Markus J.$$b0
000153422 245__ $$aQuality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019
000153422 260__ $$aDeisenhofen, München$$bDustri-Verl.$$c2020
000153422 3367_ $$2DRIVER$$aarticle
000153422 3367_ $$2DataCite$$aOutput Types/Journal article
000153422 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1606486947_22902
000153422 3367_ $$2BibTeX$$aARTICLE
000153422 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153422 3367_ $$00$$2EndNote$$aJournal Article
000153422 520__ $$aWe here report on the first neuropathological round robin trials initiated by the Quality Assurance Initiative Pathology (QuIP) in Germany in the years 2018 and 2019. Testing services as external laboratory controls were offered for IDH1-R132H immunohistochemistry in 2018 followed by a molecular trial for IDH1 and IDH2 mutations in 2019 including the rare mutational variants. Also in 2019, a trial on MGMT promoter methylation testing was offered. On a national scale, trial offers were well received with around 40 participating institutions. The international announcement of the molecular IDH1/IDH2 mutational trial achieved only moderate European outspread. Success rates in all three trials were excellent (IDH1-R132H immunohistochemistry 2018: 94%, 18 out of 20 possible points required; IDH1/IDH2 mutational status 2019: 100%, 19 out of 20 possible points required; MGMT promoter methylation 2019: 94%, 19 out of 20 possible points required) indicating that quality standards are high in the broad majority of the institutions. Trial participation also involved filling in a questionnaire asking for background information on local testing procedures. We here present a first assessment of the information collected providing unique insights in the landscape of molecular testing in neuropathology. Derived from this information we identify future challenges and provide an outlook on the development of quality assurance in the field of neuropathology.
000153422 536__ $$0G:(DE-HGF)POF3-345$$a345 - Population Studies and Genetics (POF3-345)$$cPOF3-345$$fPOF III$$x0
000153422 588__ $$aDataset connected to CrossRef
000153422 7001_ $$aFischer, Josephine$$b1
000153422 7001_ $$aGrassow-Narlik, Maja$$b2
000153422 7001_ $$aMawrin, Christian$$b3
000153422 7001_ $$aDeimling, Andreas von$$b4
000153422 7001_ $$0P:(DE-2719)2812617$$aPietsch, Torsten$$b5$$udzne
000153422 7001_ $$aReifenberger, Guido$$b6
000153422 7001_ $$aMueller, Wolf C.$$b7
000153422 7001_ $$aSommer, Clemens J.$$b8
000153422 7001_ $$aDietel, Manfred$$b9
000153422 7001_ $$aZoubaa, Saida$$b10
000153422 7001_ $$0P:(DE-HGF)0$$aLorenz, Julia$$b11$$eCorresponding author
000153422 7001_ $$0P:(DE-HGF)0$$aRothhammer-Hampl, Tanja$$b12$$eCorresponding author
000153422 773__ $$0PERI:(DE-600)2007408-6$$a10.5414/NP301278$$gVol. 39, no. 09, p. 203 - 211$$n09$$p203 - 211$$tClinical neuropathology$$v39$$x0722-5091$$y2020
000153422 909CO $$ooai:pub.dzne.de:153422$$pVDB
000153422 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812617$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000153422 9131_ $$0G:(DE-HGF)POF3-345$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vPopulation Studies and Genetics$$x0
000153422 9141_ $$y2020
000153422 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-21
000153422 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-21
000153422 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN NEUROPATHOL : 2019$$d2021-01-27
000153422 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000153422 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000153422 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-27
000153422 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000153422 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000153422 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000153422 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-27
000153422 9201_ $$0I:(DE-2719)1011009$$kBrainbank Unit Bonn$$lBrainbank Unit Bonn$$x0
000153422 980__ $$ajournal
000153422 980__ $$aVDB
000153422 980__ $$aI:(DE-2719)1011009
000153422 980__ $$aUNRESTRICTED